SCHEMBL5683160

SCHEMBL5683160

Cc1[nH]c2ccccc2c1C1=C(c2ccc(Cl)cc2Cl)C(=O)NC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 3/20 0.56
CDK4 P11802 3/20 0.56
CCND1 P24385 3/20 0.56
GSK3A P49840 2/20 0.56
CDK2 P24941 2/20 0.56
HTT P42858 2/20 0.56
LMNA P02545 2/20 0.56
MEN1 O00255 1/20 0.56
RGS12 O14924 1/20 0.56
GMNN O75496 1/20 0.56
USP2 O75604 1/20 0.56
CCNB2 O95067 1/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 1/20 0.56
CDK1 P06493 1/20 0.56
POLB P06746 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5682601 0.87 CAMK2D (0.54) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL17211124 0.84 CA1 (0.42) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL15797143 0.83 GSK3B (0.46) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL5686050 0.83 CAMK2D (0.57) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL19217082 0.81 CAMK2D (0.46) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL16512988 0.77 PRKCB (0.70) GSK3BCDK4CCND1GSK3ACDK2
SCHEMBL15797114 0.76 PRKCB (0.54) GSK3BCDK4CCND1CDK2LMNA
SCHEMBL20243386 0.76 CAMK2D (0.55) CDK4CCND1CDK2HTTLMNA
SCHEMBL19217026 0.74 CAMK2D (0.50) CDK4CCND1CDK2HTTLMNA
SCHEMBL19217019 0.74 CAMK2D (0.51) GSK3BCAMK2DPRKCBPRKCAPRKCH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350313-A1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS Agency For Science, Technology And Research (A*star) (SG) 2018-07-25 EP claimed
WO-2017048193-A1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2017-03-23 WO claimed
EP-1140070-A1 TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 SMITHKLINE BEECHAM PLC (GB) 2001-10-10 EP claimed
WO-2000038675-A1 TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 SMITHKLINE BEECHAM PLC (GB) 2000-07-06 WO claimed
US-10420754-B2 Use of maleimide derivatives for preventing and treating cancer CENTOGENE AG (DE) 2019-09-24 US disclosed
EP-3458572-A1 HUMAN STEM CELL DERIVED ENDOTHELIAL CELLS, ENDOTHELIAL- HEPATOCYTE CO-CULTURE SYSTEM AND USES THEREOF Agency for Science, Technology and Research (SG) 2019-03-27 EP disclosed
EP-3430132-A1 GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS Agency for Science, Technology and Research (SG) 2019-01-23 EP disclosed
EP-3350313-A1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS Agency For Science, Technology And Research (A*star) (SG) 2018-07-25 EP disclosed
US-9993463-B2 Use of maleimide derivatives for preventing and treating cancer CENTOGENE AG (DE) 2018-06-12 US disclosed
WO-2018009147-A1 METHOD OF GENERATING MESENCHYMAL STEM CELLS AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-01-11 WO disclosed
WO-2017200486-A1 HUMAN STEM CELL DERIVED ENDOTHELIAL CELLS, ENDOTHELIAL- HEPATOCYTE CO-CULTURE SYSTEM AND USES THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-11-23 WO disclosed
WO-2017160234-A1 GENERATION OF MIDBRAIN-SPECIFIC ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-09-21 WO disclosed
US-9724331-B2 Use of maleimide derivatives for preventing and treating leukemia CENTOGENE AG (DE) 2017-08-08 US disclosed
WO-2017048193-A1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR) (SG) 2017-03-23 WO disclosed
WO-2005028678-A9 METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY WYETH CORP (US) 2006-08-31 WO disclosed
EP-1636388-A2 METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY Wyeth (US) 2006-03-22 EP disclosed
WO-2005028678-A2 METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY WYETH (US) 2005-03-31 WO disclosed
EP-1140070-A1 TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 SMITHKLINE BEECHAM PLC (GB) 2001-10-10 EP disclosed
WO-2000038675-A1 TREATMENT OF CONDITIONS WITH A NEED FOR THE INHIBITION OF GSK-3 SMITHKLINE BEECHAM PLC (GB) 2000-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10420754-B2 Use of maleimide derivatives for preventing and treating cancer MGMT, IDH3A, CYP3A43 GSK3B 2325/4885CDK4 874/4885CCND1 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.